Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corp. to express two therapeutic compounds using C1 production platform; and the Sanofi-Aventis Deutschland GmbH to express the potential of its C1 technology to produce various types of therapeutic compounds for manufacturing protein-based vaccine and biologic drugs; and research collaboration with global biotech company to explore the potential of its C1 technology to produce an active moiety. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone561-743-8333
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$760,000.00
Profitability
Miscellaneous
Employees6
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Dyadic International (NASDAQ:DYAI) Frequently Asked Questions
What is Dyadic International's stock symbol?
Dyadic International trades on the NASDAQ under the ticker symbol "DYAI."
How were Dyadic International's earnings last quarter?
Dyadic International, Inc (NASDAQ:DYAI) issued its earnings results on Tuesday, August, 13th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.03. The biotechnology company had revenue of $0.39 million for the quarter, compared to analyst estimates of $0.40 million. View Dyadic International's Earnings History.
When is Dyadic International's next earnings date?
What price target have analysts set for DYAI?
1 brokerages have issued twelve-month target prices for Dyadic International's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Dyadic International's share price to reach $9.00 in the next year. This suggests a possible upside of 62.2% from the stock's current price. View Analyst Price Targets for Dyadic International.
What is the consensus analysts' recommendation for Dyadic International?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dyadic International.
Has Dyadic International been receiving favorable news coverage?
News coverage about DYAI stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dyadic International earned a news impact score of 0.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Dyadic International.
Are investors shorting Dyadic International?
Dyadic International saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 559,100 shares, an increase of 7.3% from the July 31st total of 521,000 shares. Based on an average trading volume of 151,200 shares, the short-interest ratio is presently 3.7 days. Currently, 3.0% of the company's stock are sold short. View Dyadic International's Current Options Chain.
Who are some of Dyadic International's key competitors?
Some companies that are related to Dyadic International include Cellectis (CLLS), Translate Bio (TBIO), Precision BioSciences (DTIL), Autolus Therapeutics (AUTL), Avrobio (AVRO), Solid Biosciences (SLDB), Tcr2 Therapeutics (TCRR), Harpoon Therapeutics (HARP), Agenus (AGEN), Scholar Rock (SRRK), Replimune Group (REPL), Adverum Biotechnologies (ADVM), Prevail Therapeutics (PRVL), Gritstone Oncology (GRTS) and BioCryst Pharmaceuticals (BCRX).
What other stocks do shareholders of Dyadic International own?
Who are Dyadic International's key executives?
Dyadic International's management team includes the folowing people:
- Mr. Mark A. Emalfarb, Founder, CEO, Pres & Director (Age 63)
- Ms. Ping Wang Rawson, Chief Accounting Officer & Principal Financial Officer (Age 43)
- Mr. Matthew S. Jones, Managing Director of Bus. Devel. & Licensing (Age 41)
- Dr. Ronen Tchelet, VP of Research & Bus. Devel. (Age 61)
- Ms. Ana Gómez Rodriguez, Sec. of the Board
Who are Dyadic International's major shareholders?
Dyadic International's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bandera Partners LLC (5.69%), Vanguard Group Inc. (2.65%), Northeast Financial Consultants Inc (0.93%), Bank of America Corp DE (0.34%), Pekin Hardy Strauss Inc. (0.23%) and BlackRock Inc. (0.20%). View Institutional Ownership Trends for Dyadic International.
Which major investors are buying Dyadic International stock?
DYAI stock was bought by a variety of institutional investors in the last quarter, including Bandera Partners LLC, Vanguard Group Inc., Northeast Financial Consultants Inc, Bank of America Corp DE, Pekin Hardy Strauss Inc., BlackRock Inc., Cedar Brook Financial Partners LLC and Advisor Group Inc.. View Insider Buying and Selling for Dyadic International.
How do I buy shares of Dyadic International?
Shares of DYAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Dyadic International's stock price today?
One share of DYAI stock can currently be purchased for approximately $5.55.
How big of a company is Dyadic International?
What is Dyadic International's official website?
How can I contact Dyadic International?
Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The biotechnology company can be reached via phone at 561-743-8333 or via email at [email protected]
MarketBeat Community Rating for Dyadic International (NASDAQ DYAI)
MarketBeat's community ratings are surveys of what our community members think about Dyadic International and other stocks. Vote "Outperform" if you believe DYAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DYAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
